Are you Dr. Spencer-Green?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Connect with colleagues in the same hospital or clinic
You already have 34 invites waiting! - Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
130 Waverly St
Vertex Corp
Cambridge, MA 02139Phone+1 617-444-6398- Is this information wrong?
Summary
- Dr. George Spencer-Green, MD is a rheumatologist in Cambridge, Massachusetts. He is currently licensed to practice medicine in Ohio.
Education & Training
University of Cincinnati Medical Center/College of MedicineFellowship, Rheumatology, 1978 - 1979
Christ HospitalResidency, Internal Medicine, 1976 - 1977
Cincinnati Children's Hospital Medical CenterResidency, Pediatrics, 1975 - 1976- University of Cincinnati Medical Center/College of MedicineInternship, Internal Medicine, 1974 - 1975
Columbia University Vagelos College of Physicians and SurgeonsClass of 1974
Certifications & Licensure
OH State Medical License 1975 - 2018
Awards, Honors, & Recognition
- Fellow (FACR) American College of Rheumatology
Clinical Trials
- Single and Multiple Dose Escalation Study of VX-509 in Healthy Subjects Start of enrollment: 2008 Oct 01
Publications & Presentations
PubMed
- 14 citationsComparative assessment of clinical response in patients with rheumatoid arthritis between PF-05280586, a proposed rituximab biosimilar, and rituximabJason H. Williams, Matthew M. Hutmacher, Matthew L. Zierhut, Jean‐Claude Becker, Barry Gumbiner, George Spencer‐Green, L.A. Melia, Kai-Hsin Liao, Matthew Suster, Dongh...> ;British Journal of Clinical Pharmacology. 2016 Dec 1
- 43 citationsA phase I pharmacokinetics trial comparing PF‐05280586 (a potential biosimilar) and rituximab in patients with active rheumatoid arthritisStanley N. Cohen, Paul Emery, Maria Greenwald, Donghua Yin, Jean‐Claude Becker, L.A. Melia, Ruifeng Li, Barry Gumbiner, Dolca Thomas, George Spencer‐Green, Xu Meng> ;British Journal of Clinical Pharmacology. 2016 Jul 1
- 409 citationsResults of a phase IIa study of VX-809, an investigational CFTR corrector compound, in subjects with cystic fibrosis homozygous for the F508del-CFTR mutationJohn P. Clancy, Steven M. Rowe, Frank J. Accurso, Moira L. Aitken, Raouf S. Amin, Melissa A. Ashlock, Manfred Ballmann, Michael P. Boyle, Inez Bronsveld, Preston W. Ca...> ;Thorax. 2012 Jan 1
- Join now to see all
Press Mentions
TLC to Present Potential Cartilage-Protecting Effects of TLC599 on the Knee at 2019 ACR Annual MeetingOctober 7th, 2019- TLC Announces Part 1 Analysis of TLC590 Phase II Clinical Trial for Postsurgical Pain Management Following BunionectomyJune 14th, 2019
Can Repeat Injections Improve Knee OA Pain?March 2nd, 2024
Grant Support
- Wide Field Microscopy In Raynaud'S PhenomenonNational Center For Research Resources1985
- Familial Alterations On Cell Mediated Immunity In SLENational Center For Research Resources1985
Professional Memberships
- Fellow
